← Back to Search

Anti-bacterial

Initial Treatment for Acute Bacterial Skin Infections (ABSSSI) Caused by Staphylococcus Aureus

Hamilton, Canada
Phase 2
Waitlist Available
Research Sponsored by PolyMedix, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up eradication at end of treatment (day 7/8)
Awards & highlights
Approved for 5 Other Conditions
No Placebo-Only Group

Summary

The study investigates the safety and efficacy of PMX-30063 in patients treated for acute bacterial skin and skin-structure infection (ABSSSI).

See full description
Eligible Conditions
  • Cellulitis
  • Staphylococcus aureus

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~eradication at end of treatment (day 7/8)
This trial's timeline: 3 weeks for screening, Varies for treatment, and eradication at end of treatment (day 7/8) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
The Primary objective of this study is to assess the efficacy of PMX-30063 in patients treated for acute bacterial skin and skin-structure infection (ABSSSI).

Awards & Highlights

Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: PMX-30063Experimental Treatment1 Intervention
3 arms of PMX-300063
Group II: Daptomycin.Active Control1 Intervention
Daptomycin will be administered according to the approved product monograph information for ABSSSI.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Brilacidin
Not yet FDA approved

Find a Location

Closest Location:NCT01211470· Hamilton, Canada

Who is running the clinical trial?

PolyMedix, Inc.Lead Sponsor
1 Previous Clinical Trials
17 Total Patients Enrolled
~14 spots leftby Feb 2026